DelMar Pharmaceuticals reaches halfway enrollment point for VAL-083 trial
DelMar Pharmaceuticals announced that its Phase 2 study testing VAL-083 in patients with newly diagnosed glioblastoma multiforme, or GBM, has achieved its halfway enrollment point. This trial, targeted to enroll up to thirty patients, is a single-arm, open-label study testing VAL-083 in combination with standard radiotherapy in GBM patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase, or MGMT, gene. An estimated 60% of GBM patients possess an unmethylated MGMT gene, which confers a more limited response to current standard of care treatment as well as a lower survival probability. This clinical trial was initiated in February 2017 and is being conducted at the Sun Yat-sen University Cancer Center, or SYSUCC, in Guangzhou, China in collaboration with Guangxi Wuzhou Pharmaceutical Company. The Company is pleased to report that for the 15 patients enrolled to date, 11 have completed their prospectively planned Magnetic Resonance Imaging, or MRI, scans and have had their initial assessment for tumor progression.